TWI891735B - 新穎的巨環化合物、其製備方法及含有其之醫藥組合物 - Google Patents

新穎的巨環化合物、其製備方法及含有其之醫藥組合物

Info

Publication number
TWI891735B
TWI891735B TW110106890A TW110106890A TWI891735B TW I891735 B TWI891735 B TW I891735B TW 110106890 A TW110106890 A TW 110106890A TW 110106890 A TW110106890 A TW 110106890A TW I891735 B TWI891735 B TW I891735B
Authority
TW
Taiwan
Prior art keywords
methyl
dioxo
ethyl
ppm
general procedure
Prior art date
Application number
TW110106890A
Other languages
English (en)
Chinese (zh)
Other versions
TW202144367A (zh
Inventor
克沙巴 衛柏
克勞斯 西多夫
迪帝爾 杜蘭德
馬利歐 久里斯
阿帕德 奇士
佐爾坦 默德拉茲
馬克 莫爾納
米克羅司 倪兒祺
莫妮卡 魯達索瓦
阿提拉 薩皮
西爾維 貝爾格
薇樂利 迪維維耶
維吉尼 馬丁尼
伊莎貝爾 特雷特
西追 文森
Original Assignee
法商施維雅藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商施維雅藥廠 filed Critical 法商施維雅藥廠
Publication of TW202144367A publication Critical patent/TW202144367A/zh
Application granted granted Critical
Publication of TWI891735B publication Critical patent/TWI891735B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW110106890A 2020-02-28 2021-02-26 新穎的巨環化合物、其製備方法及含有其之醫藥組合物 TWI891735B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20305207.1 2020-02-28
EP20305207 2020-02-28

Publications (2)

Publication Number Publication Date
TW202144367A TW202144367A (zh) 2021-12-01
TWI891735B true TWI891735B (zh) 2025-08-01

Family

ID=70977485

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110106890A TWI891735B (zh) 2020-02-28 2021-02-26 新穎的巨環化合物、其製備方法及含有其之醫藥組合物

Country Status (12)

Country Link
US (1) US20230097678A1 (https=)
EP (1) EP4110776A1 (https=)
JP (1) JP7757298B2 (https=)
KR (1) KR20220148851A (https=)
CN (1) CN115151538B (https=)
AR (1) AR121435A1 (https=)
AU (1) AU2021226994A1 (https=)
BR (1) BR112022016286A2 (https=)
IL (1) IL295595B1 (https=)
MX (1) MX2022010673A (https=)
TW (1) TWI891735B (https=)
WO (1) WO2021170774A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021014680A (es) 2019-05-31 2022-04-06 Ube Corp Derivado de benzotriazol.
CN114028374A (zh) * 2021-12-01 2022-02-11 江苏省人民医院（南京医科大学第一附属医院） 富马酸二甲酯在制备用于保护胰岛β细胞功能的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160318917A1 (en) * 2013-12-18 2016-11-03 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160318917A1 (en) * 2013-12-18 2016-11-03 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators

Also Published As

Publication number Publication date
US20230097678A1 (en) 2023-03-30
IL295595A (en) 2022-10-01
AU2021226994A1 (en) 2022-09-08
BR112022016286A2 (pt) 2022-12-13
AR121435A1 (es) 2022-06-08
CN115151538B (zh) 2026-02-27
CA3170840A1 (en) 2021-09-02
KR20220148851A (ko) 2022-11-07
IL295595B1 (en) 2026-01-01
JP7757298B2 (ja) 2025-10-21
CN115151538A (zh) 2022-10-04
JP2023515572A (ja) 2023-04-13
TW202144367A (zh) 2021-12-01
EP4110776A1 (en) 2023-01-04
WO2021170774A1 (en) 2021-09-02
MX2022010673A (es) 2022-09-23

Similar Documents

Publication Publication Date Title
EP2603513B1 (en) Heterocyclic compound and use thereof as ampa receptor positive allosteric modulator
US10081625B2 (en) 5-methyl-1,2,4-oxadiazol-3-yl compounds
US12358875B2 (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis
US12559504B2 (en) Benzotriazole derivative
EP3441389B1 (en) Pyrazole-oxazolidinone compound for anti-hepatitis b virus
WO1999051572A1 (en) Sulfonamide derivatives
WO2018181345A1 (ja) 複素環化合物
TWI891735B (zh) 新穎的巨環化合物、其製備方法及含有其之醫藥組合物
CA2696237A1 (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
CA3170840C (en) Macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them
TW200904403A (en) Tricyclic aryl compounds
EA050508B1 (ru) Новые макроциклические соединения, способ их получения и содержащие их фармацевтические композиции
EP2396320B1 (fr) Derives de 3-benzofuranyl-indol-2-one substitues en position 3, leur preparation et leur application en therapeutique
EP2396319B1 (fr) Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
HK40078242A (en) New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them
US12378260B2 (en) Benzotriazole compound
RU2840112C2 (ru) Производные бензотриазола
CZ216895A3 (en) Novel derivatives of 3-hydroxyanthranilic acid, process and intermediates of their preparation, novel pharmaceutical preparations and their use
US20180230160A1 (en) 2-amino-7a-phenyl-3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyridines as bace1 inhibitors
CA3160543A1 (en) Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
CN114787166A (zh) 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用
HK1182701A (en) Heterocyclic compound and use thereof as ampa receptor positive allosteric modulator